- Eloxx Pharmaceuticals Provides ELX-02 and ZKN-013 Program Updates
- Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to license ZKN-013 for rare dermatological diseases
- Eloxx Pharmaceuticals Reports Third Quarter 2023 Financial and Operating Results and Provides Business Update
- Eloxx Pharmaceuticals Reports Additional Confirmation that All Nonsense Mutation Alport Syndrome Patients Treated with ELX-02 in Phase 2 Study had Improvement in Kidney Morphology and Clinical Benefit of Reduction or Stabilization of Proteinuria
- Eloxx Pharmaceuticals Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
- Eloxx Pharmaceuticals Reports Independent Confirmation of Positive Biopsy Results in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport Syndrome
- Eloxx Pharmaceuticals Provides Program Updates on ELX-02 and ZKN-013
- Eloxx Pharmaceuticals Reports Second Quarter 2023 Financial and Operating Results and Provides Business Update
- Eloxx Pharmaceuticals Reports Drug Response in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport Syndrome
- Eloxx Pharmaceuticals Granted Extension by Nasdaq to Regain Compliance with the Market Value of Listed Securities Continued Listing Requirement
More ▼
Key statistics
On Tuesday, Eloxx Pharmaceuticals Inc (3970:BER) closed at 6.40, -14.67% below its 52-week high of 7.50, set on May 16, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.00 |
---|---|
High | 0.00 |
Low | 0.00 |
Bid | 6.20 |
Offer | 6.90 |
Previous close | 6.40 |
Average volume | -- |
---|---|
Shares outstanding | 3.14m |
Free float | 3.01m |
P/E (TTM) | -- |
Market cap | 2.53m USD |
EPS (TTM) | -9.06 USD |
Data delayed at least 15 minutes, as of May 16 2023 11:22 BST.
More ▼